Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > PR

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jun 10, 2021 4:23pm

269 Views

Post# 33366862

RE:RE:PR

I am sure there is a good reason why they release a PR like this after the close but I really don't know what it could be. It would appear that this is the best way to lose any minimal aount of value you would get from such a PR as the algo's may not give it any value tomorrow morning.

The bigger question is what exactly does "an update on its ocology program" refer to? It does not say they will give an update on the progress in their phase I trial. That may be included in such an update but given this language, we should probably keep our expectations low for getting any meaningful info about the phase I trial at this session.

scarlet1967 wrote:
"Theratechnologies' President and Chief Executive Officer Paul Lvesque and Senior Vice President and Chief Medical Officer Christian Marsolais, Ph.D. will also give an update on its oncology program."